Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
The reversibility of amivantamab-related toxicities suggests its promising utility in patients with EGFR exon 20 insertion mutations NSCLC.
Authors
- Jing Zhang (ORCID: https://orcid.org/0000-0003-3548-6138)
- Wenjie Li (ORCID: https://orcid.org/0000-0001-5285-8939)
Institutions
- Fudan University (CN)
- Nanfang Hospital (CN)
- Shanghai Second People's Hospital (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- BMC Pulmonary Medicine
- Published
- 2025-02-06
- DOI
- https://doi.org/10.1186/s12890-025-03509-z
- Citations
- 7
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 10.63